- Home
- SKYE vs LANV Comparison
SKYE vs LANV Comparison
Compare SKYE & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- LANV
- Stock Information
- Founded
- SKYE 2012
- LANV 2015
- Country
- SKYE United States
- LANV China
- Employees
- SKYE N/A
- LANV N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- LANV Blank Checks
- Sector
- SKYE Health Care
- LANV Finance
- Exchange
- SKYE Nasdaq
- LANV Nasdaq
- Market Cap
- SKYE 172.9M
- LANV 196.8M
- IPO Year
- SKYE N/A
- LANV N/A
- Fundamental
- Price
- SKYE $5.73
- LANV $1.72
- Analyst Decision
- SKYE Strong Buy
- LANV
- Analyst Count
- SKYE 5
- LANV 0
- Target Price
- SKYE $18.40
- LANV N/A
- AVG Volume (30 Days)
- SKYE 142.7K
- LANV 89.8K
- Earning Date
- SKYE 11-09-2024
- LANV 08-26-2024
- Dividend Yield
- SKYE N/A
- LANV N/A
- EPS Growth
- SKYE N/A
- LANV N/A
- EPS
- SKYE N/A
- LANV N/A
- Revenue
- SKYE N/A
- LANV $409,961,427.00
- Revenue This Year
- SKYE N/A
- LANV N/A
- Revenue Next Year
- SKYE N/A
- LANV $76.77
- P/E Ratio
- SKYE N/A
- LANV N/A
- Revenue Growth
- SKYE N/A
- LANV N/A
- 52 Week Low
- SKYE $1.44
- LANV $0.91
- 52 Week High
- SKYE $19.41
- LANV $4.70
- Technical
- Relative Strength Index (RSI)
- SKYE 43.81
- LANV 58.51
- Support Level
- SKYE $5.03
- LANV $1.60
- Resistance Level
- SKYE $7.11
- LANV $1.82
- Average True Range (ATR)
- SKYE 0.60
- LANV 0.14
- MACD
- SKYE -0.10
- LANV -0.01
- Stochastic Oscillator
- SKYE 15.30
- LANV 67.38
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.